BPC-157
Body Protection Compound-157
A synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Extensively studied for tissue repair, gastroprotection, and anti-inflammatory properties across multiple organ systems.
What is it?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a protein found in human gastric juice, where it is believed to play a role in gastrointestinal mucosal protection and healing. The peptide was first isolated and characterized by researchers studying the cytoprotective properties of gastric secretions.
Since its discovery, BPC-157 has been the subject of extensive preclinical research — with published studies spanning tendon and ligament healing, bone fracture repair, muscle injury recovery, gastrointestinal protection, neuroprotection, and cardiovascular effects. Human exposure is not new: Pliva took the peptide into clinical trials for inflammatory bowel disease in the 2000s under the codes PL-10, PLD-116 and PL 14736, and reported it as safe in that setting. What has never followed is a published, controlled efficacy readout in humans for any of the musculoskeletal uses the compound is now sold for — which is why this entry is graded low evidence rather than moderate.
Mechanism of Action
BPC-157's mechanism of action is not fully elucidated, but preclinical research has identified several pathways through which it appears to exert its effects:
Angiogenesis / VEGF Pathway
BPC-157 has been shown to promote the formation of new blood vessels by upregulating vascular endothelial growth factor (VEGF) and its receptor VEGFR2. This enhanced blood supply is hypothesized to accelerate tissue repair in tendons, muscles, and the GI tract.
Nitric Oxide (NO) System
Research indicates BPC-157 modulates the nitric oxide system, which plays critical roles in vasodilation, inflammation, and tissue repair. It appears to interact with both NOS (nitric oxide synthase) and the NO-mediated pathway.
Growth Hormone Receptor Expression
A 2018 study demonstrated that BPC-157 enhances growth hormone receptor (GHR) expression in tendon fibroblasts, suggesting a mechanism by which it may accelerate connective tissue repair independent of exogenous GH administration.
Dopaminergic System Modulation
In vitro and in vivo studies have shown BPC-157 interacts with the dopaminergic system, modulating dopamine receptor expression and turnover. This may underlie observed effects on mood, motivation, and neurological recovery in animal models.
FAK-Paxillin Signaling
BPC-157 appears to activate the FAK-paxillin pathway, which is essential for cell migration, adhesion, and tissue organization during wound healing. This mechanism has been observed across multiple tissue types.
Published Research
BPC-157 appears in roughly 200 PubMed-indexed records published between 1991 and 2025, the large majority animal and in vitro work from a small number of groups. Human data is thin and old: a Croatian inflammatory-bowel-disease programme (PL 14736) in the 2000s, and a 2-patient intravenous safety pilot in 2025. Neither speaks to whether it repairs tendon in people. Filter by study type below.
Safety of Intravenous BPC-157 in Humans: A 2-Patient Pilot
Two adults at a private Florida clinic received 10 mg then 20 mg IV infusions; no changes in cardiac, liver, kidney, thyroid or glucose markers and no reported side effects. Both had taken IV BPC-157 before enrolling, there was no control arm, and n=2 supports a safety signal only — not efficacy.
BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Systematic review of the BPC-157 literature to June 2024 across PubMed, Cochrane and Embase. Finds preclinical support for healing in fracture, tendon, ligament and muscle injury, and notes the compound is used by clinicians and athletes despite lacking FDA approval and being banned in professional sport.
BPC-157 Enhances Growth Hormone Receptor Expression in Tendon Fibroblasts
BPC 157 increased growth hormone receptor expression in cultured tendon fibroblasts in a time- and dose-dependent way, proposed as one route by which it may influence tendon healing.
BPC-157 and Blood Vessels
Review of the vascular work on BPC 157 — angiogenic response, NO-system interaction, and vessel recruitment around ischaemic tissue — the basis for the angiogenesis mechanism claimed for this peptide.
Traumatic Brain Injury in Mice and BPC-157
In a falling-weight TBI model in mice, BPC 157 (10 µg or 10 ng/kg i.p.) reduced haemorrhagic lesions and brain oedema and improved the conscious/unconscious/death ratio across a range of impact forces.
BPC-157 as Therapy for Muscle Crush Injury in the Rat
Gastric pentadecapeptide BPC 157 improved healing of crushed gastrocnemius muscle in rats on functional, biomechanical, macroscopic and histological measures.
BPC-157 and Gastric Ulcer Protection in Rats
Intramuscular and intragastric BPC 157 reduced ulcer area and accelerated healing in induced acute and chronic gastric ulcer in rats, with inhibition ratios of 45.7–65.6% at 400–800 ng/kg; the intramuscular route outperformed intragastric.
BPC-157 Interactions with Adrenergic and Dopaminergic Systems
Early pharmacology showing BPC 157 interacts with adrenergic and dopaminergic systems in rodent models — the origin of the claim that it modulates dopamine signalling.
Dosing Protocols
The following dosing information is derived from published research and clinical protocols. This is not medical advice.
→ Full BPC-157 dosage guide — how it was dosed in research vs. community protocols, units explained, reconstitution math, and current 503A/PCAC status, with primary sources.
Side Effects & Contraindications
Reported Side Effects
Based on limited human data and anecdotal reports. Most effects are mild and transient:
Contraindications & Cautions
Limited clinical data means contraindications are not fully established:
Legal Status
BPC-157's legal status varies significantly by country and has been in flux since the FDA's 2023–2025 enforcement actions against compounded peptides.
Common Stacking Protocols
BPC-157 is frequently combined with other peptides for synergistic effects. The following stacks are commonly referenced in research and clinical practice.
BPC-157 + TB-500
High SynergyThe most common peptide stack. BPC-157 promotes angiogenesis and collagen synthesis while TB-500 enhances cell migration and reduces inflammation. Together, they address repair from complementary angles.
BPC-157 + GHK-Cu
Moderate SynergyGHK-Cu's broad gene expression modulation combined with BPC-157's tissue repair properties. Used in protocols targeting skin quality, wound healing, and systemic anti-aging.
BPC-157 + CJC-1295 + Ipamorelin
Moderate SynergyAdding growth hormone secretagogues amplifies the recovery environment. CJC-1295/Ipamorelin elevate baseline GH, while BPC-157 targets specific tissue repair.
Frequently Asked Questions
What is BPC-157 used for?+
BPC-157 is primarily studied for tissue repair and healing. Published research has investigated its effects on tendons, ligaments, muscles, the gastrointestinal tract, bone, and neurological tissue. It is not FDA-approved for any therapeutic use in humans.
Is BPC-157 legal?+
Legal status varies by country. In the US, it was placed on the FDA's Category 2 restricted list in 2023 but is expected to be reinstated for compounding under 503A. In many other countries, it is available as a research chemical. See the Legal Status section above for a country-by-country breakdown.
How do you inject BPC-157?+
BPC-157 is most commonly administered via subcutaneous injection, typically near the site of injury for localized effects. It can also be injected intramuscularly. The peptide must first be reconstituted from lyophilized powder using bacteriostatic water. See our Mixing & Administration Guide for step-by-step instructions.
What are the side effects of BPC-157?+
Based on limited human data and anecdotal reports, side effects appear mild and may include nausea, dizziness, injection site redness, and headache. The 2025 pilot study found no serious adverse events at IV doses up to 20mg. However, long-term human safety data is not yet available.
Can you take BPC-157 orally?+
Some research has been conducted using oral administration of BPC-157, particularly for gastrointestinal applications. Oral bioavailability is believed to be lower than injectable routes, and oral capsule forms are available from some compounding pharmacies. Research on oral vs. injectable efficacy is limited.
How long does BPC-157 take to work?+
Anecdotal reports suggest effects may be noticed within a few days to two weeks, depending on the severity of the condition being addressed. Research protocols typically run 4–8 weeks. Individual response varies significantly.
Does BPC-157 need to be refrigerated?+
Yes. Lyophilized (powder) BPC-157 should be stored at -20°C for long-term storage or 2–8°C (refrigerator) for short-term. Once reconstituted, the solution should be refrigerated at 2–8°C and used within 28 days. Avoid repeated freeze-thaw cycles.
Is BPC-157 a steroid?+
No. BPC-157 is a peptide — a short chain of 15 amino acids. It is not a steroid, not a hormone, and does not directly affect testosterone, estrogen, or other steroid hormones. Its mechanism of action involves growth factors, nitric oxide pathways, and cell signaling — entirely different from anabolic steroids.
Can BPC-157 cause cancer?+
This is an area of theoretical concern, not established fact. Because BPC-157 promotes angiogenesis (new blood vessel formation), there is a hypothesis that it could theoretically support tumor growth in individuals with existing cancers. No published study has demonstrated a carcinogenic effect. However, most researchers recommend avoiding BPC-157 in individuals with active malignancies as a precaution.
What is the difference between BPC-157 and TB-500?+
Both are tissue repair peptides, but they work through different mechanisms. BPC-157 primarily promotes angiogenesis, modulates the nitric oxide system, and enhances growth factor receptor expression. TB-500 (Thymosin Beta-4) acts mainly through actin regulation, cell migration, and anti-inflammatory pathways. They are frequently stacked together for synergistic effects.
References
- [review] Sever AZ, et al. "Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation." Eur J Pharmacol, 2019;847:130-142. PMID: 30690000.
- [review] Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol, 2011. PMID: 21030672.
- [pubmed] Seiwerth S, et al. "BPC 157 and standard angiogenic growth factors." Life Sci, 2018. PMID: 29998800.
Every source above is indexed in PubMed and was resolved to its record before it was printed. Grey Peptides links to no vendor and sells nothing.
Deep dive: BPC-157 articles
BPC-157 Complete Guide → BPC-157 vs TB-500 → BPC-157 + TB-500 Stack Guide → Best Peptides for Healing →Sources & Citations
All research cited on this page links to published studies indexed in PubMed. Molecular data sourced from PubChem (CID 108101). Dosing protocols compiled from published clinical protocols and peer-reviewed research literature. Legal status information current as of April 2026. This page is reviewed and updated monthly.
Medical Disclaimer: This content is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare professional with any questions regarding a medical condition or treatment.